Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells

被引:19
作者
Shrestha, Sumi [1 ,2 ,3 ]
Sorolla, Anabel [2 ,3 ]
Fromont, Jane [4 ]
Blancafort, Pilar [2 ,3 ]
Flematti, Gavin R. [1 ]
机构
[1] Univ Western Australia, Sch Mol Sci, Crawley, WA 6009, Australia
[2] Univ Western Australia, QEII Med Ctr, Harry Perkins Inst Med Res, Canc Epigenet, Crawley, WA 6009, Australia
[3] Univ Western Australia, Ctr Med Res, Crawley, WA 6009, Australia
[4] Western Australian Museum, Welshpool, WA 6106, Australia
基金
澳大利亚研究理事会; 美国国家卫生研究院; 英国医学研究理事会;
关键词
triple negative breast cancer; aurantoside C; marine sponge; apoptosis; cell cycle analysis; NF-KAPPA-B; TETRAMIC ACID GLYCOSIDES; ACTIVATED PROTEIN-KINASES; MARINE NATURAL-PRODUCTS; ANTITUMOR-ACTIVITY; STELLETTIN B; PATHWAY; PROLIFERATION; SPONGE; CYCLE;
D O I
10.3390/md16100361
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Triple negative breast cancer (TNBC) is a subtype of breast cancers that currently lacks effective targeted therapy. In this study, we found that aurantoside C (C828), isolated from the marine sponge Manihinealynbeazleyae collected from Western Australia, exhibited higher cytotoxic activities in TNBC cells compared with non-TNBC (luminal and normal-like) cells. The cytotoxic effect of C828 was associated to the accumulation of cell at S-phase, resulting in the decline of cyclin D1, cyclin E1, CDK4, and CDK6, and an increase in p21. We also found that C828 inhibited the phosphorylation of Akt/mTOR and NF-kB pathways and increased the phosphorylation of p38 MAPK and SAPK/JNK pathways, leading to apoptosis in TNBC cells. These effects of C828 were not observed in non-TNBC cells at the concentrations that were cytotoxic to TNBC cells. When compared to the cytotoxic effect with the chemotherapeutic drugs doxorubicin and cisplatin, C828 was found to be 20 times and 35 times more potent than doxorubicin and cisplatin, respectively. These results indicate that C828 could be a promising lead for developing new anticancer agents that target TNBC cells.
引用
收藏
页数:20
相关论文
共 81 条
  • [1] Aurantoside J: a New Tetramic Acid Glycoside from Theonella swinhoei. Insights into the Antifungal Potential of Aurantosides
    Angawi, Rihab F.
    Bavestrello, Giorgio
    Calcinai, Barbara
    Dien, Henny Adeleida
    Donnarumma, Giovanna
    Tufano, Maria Antonietta
    Paoletti, Iole
    Grimaldi, Elena
    Chianese, Giuseppina
    Fattorusso, Ernesto
    Taglialatela-Scafati, Orazio
    [J]. MARINE DRUGS, 2011, 9 (12): : 2809 - 2817
  • [2] NF-KB activation in human breast cancer specimens and its role in cell proliferation and apoptosis
    Biswas, DK
    Shi, Q
    Baily, S
    Strickland, I
    Ghosh, S
    Pardee, AB
    Iglehart, JD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (27) : 10137 - 10142
  • [3] Marine Natural Products Chemistry: Past, Present, and Future
    Capon, Robert J.
    [J]. AUSTRALIAN JOURNAL OF CHEMISTRY, 2010, 63 (06) : 851 - 854
  • [4] Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype
    Cheang, Maggie C. U.
    Voduc, David
    Bajdik, Chris
    Leung, Samuel
    McKinney, Steven
    Chia, Stephen K.
    Perou, Charles M.
    Nielsen, Torsten O.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1368 - 1376
  • [5] Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5
    Chen, Yali
    Zhou, Qianxiang
    Zhang, Lei
    Zhong, Yuxu
    Fan, Guanwei
    Zhang, Zhe
    Wang, Ran
    Jin, Meihua
    Qiu, Yuling
    Kong, Dexin
    [J]. ONCOTARGET, 2017, 8 (17) : 28906 - 28921
  • [6] Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
    Corkery, B.
    Crown, J.
    Clynes, M.
    O'Donovan, N.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (05) : 862 - 867
  • [7] Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
    Cossa, Giacomo
    Gatti, Laura
    Cassinelli, Giuliana
    Lanzi, Cinzia
    Zaffaroni, Nadia
    Perego, Paola
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (05) : 883 - 894
  • [8] A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors
    Creighton, C. J.
    [J]. ONCOGENE, 2007, 26 (32) : 4648 - 4655
  • [9] mTOR and cancer therapy
    Easton, J. B.
    Houghton, P. J.
    [J]. ONCOGENE, 2006, 25 (48) : 6436 - 6446
  • [10] Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
    El Guerrab, Abderrahim
    Bamdad, Mahchid
    Kwiatkowski, Fabrice
    Bignon, Yves-Jean
    Penault-Llorca, Frederique
    Aubel, Corinne
    [J]. ONCOTARGET, 2016, 7 (45) : 73618 - 73637